QbD approach to investigate product and process variabilities for brain targeting liposomes

Journal of Liposome Research

Volumn 25, Issue 3, 2015, Pages 175-190

  Kamal, Nahid ^a,b   Cutie, Anthony J ^b   Habib, Muhammad J ^a   Zidan, Ahmed S ^c,d  

^a HOWARD UNIVERSITY   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c Zagazig University   (Egypt)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Citalopram hydrobromide; glycosylated vectors; optimization; pegylated liposomes; quality by design

Indexed keywords

CITALOPRAM; DICETYL PHOSPHATE; LIPOSOME; MACROGOL; N ACETYLGLUCOSAMINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIAL CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; ENDOTHELIUM CELL; FREEZE THAWING; IN VITRO STUDY; LIPOSOMAL DELIVERY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SURFACE CHARGE; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION;

EID: 84939476837     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2014.968854     Document Type: Article

References (44)

1. Almer G, Frascione D, Pali-Scholl I, et al. (2012). Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm 10:175-86.
2. Atobe K, Ishida T, Ishida E, et al. (2007). In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 30:972-8.
3. Baumann P, Rochat B. (1995). Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10:15-21.
4. Borlongan CV, Emerich DF. (2003). Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull 60:297-306.
5. Bruckner JV, Weil WB. (1999). Biological factors which may influence an older child's or adolescent's responses to toxic chemicals. Regul Toxicol Pharmacol 29:158-64.
6. Casals E, Galán AM, Escolar G, et al. (2003). Physical stability of liposomes bearing hemostatic activity. Chem Phys Lipids 125:139-46.
7. El-Nesr OH, Yahiya SA, El-Gazayerly ON. (2010). Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharm J 18:217-24.
8. Erdlenbruch B, Alipour M, Fricker G, et al. (2003). Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 140:1201-10.
9. Evjen TJ, Hagtvet E, Nilssen EA, et al. (2011). Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Eur J Pharm Sci 43: 318-24.
10. Fang JY, Hwang TL, Huang YL, Fang CL. (2006). Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol. Int J Pharm 310:131-8.
11. Farrell CL, Pardridge WM. (1991). Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci USA 88:5779-83.
12. Franzen U, Ostergaard J. (2012). Physico-chemical characterization of liposomes and drug substance-liposome interactions in pharmaceutics using capillary electrophoresis and electrokinetic chromatography. J Chromatogr A 1267:32-44.
13. Galovic Rengel R, Barisic K, Pavelic Z, et al. (2002). High efficiency entrapment of superoxide dismutase into mucoadhesive chitosancoated liposomes. Eur J Pharm Sci 15:441-8.
14. Huang DW, Shen SC, Wu JS. (2009). Effects of caffeic acid and cinnamic acid on glucose uptake in insulin-resistant mouse hepatocytes. J Agric Food Chem 57:7687-92.
15. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88:157-60.
16. Ishii T, Asai T, Oyama D, et al. (2012). Treatment of cerebral ischemiareperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J 27:1362-70.
17. Jeon HS, Seo JE, Kim MS, et al. (2013). A retinyl palmitate-loaded solid lipid nanoparticle system: effect of surface modification with dicetyl phosphate on skin permeation in vitro and anti-wrinkle effect in vivo. Int J Pharm 452:311-20.
18. Knudsen NO, Ronholt S, Salte RD, et al. (2012). Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm 81: 532-9.
19. Liang X, Mao G, Ng KY. (2004). Mechanical properties and stability measurement of cholesterol-containing liposome on mica by atomic force microscopy. J Colloid Interface Sci 278:53-62.
20. Liu B, Mazouchi A, Gradinaru CC. (2010). Trapping single molecules in liposomes: surface interactions and freeze-thaw effects. J Phys Chem B 114:15191-8.
21. Magin RL, Niesman MR. (1984). Temperature-dependent permeability of large unilamellar liposomes. Chem Phys Lipids 34: 245-56.
22. Manosroi A, Podjanasoonthon K, Manosroi J. (2002). Development of novel topical tranexamic acid liposome formulations. Int J Pharm 235: 61-70.
23. Matsumura H, Verbich SV, Dimitrova MN. (2001). Surface conductivity of counter ions on protein-adsorbed lipid liposomes. Colloids Surf A Physicochem Eng Asp 192:331-6.
24. Mayer LD, Hope MJ, Cullis PR, Janoff AS. (1985). Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta 817:193-6.
25. Mishima K, Satoh K, Suzuki K. (1997). Increase in molecular order of phospholipid membranes due to osmotic stress by polyethylene glycol. Colloids Surf B Biointerfaces 10:113-17.
26. Ohtsuki S, Terasaki T. (2007). Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-58.
27. Orthmann A, Zeisig R, Suss R, et al. (2012). Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRPtargeting on the therapeutic result. Pharm Res 29:1949-59.
28. Pardridge WM. (2003). Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90-105, 51.
29. Patty PJ, Frisken BJ. (2006). Direct determination of the numberweighted mean radius and polydispersity from dynamic light-scattering data. Appl Opt 45:2209-16.
30. Qin Y, Fan W, Chen H, et al. (2010). In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 18: 536-49.
31. Riviere C, Martina MS, Tomita Y, et al. (2007). Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. Radiology 244:439-48.
32. Senzolo M, Ferronato C, Burra P. (2009). Neurologic complications after solid organ transplantation. Transpl Int 22:269-78.
33. Shestov AA, Emir UE, Kumar A, et al. (2011). Simultaneous measurement of glucose transport and utilization in the human brain. Am J Physiol Endocrinol Metab 301:E1040-9.
34. Suzuki T, Ichihara M, Hyodo K, et al. (2012). Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm 436:636-43.
35. Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-60.
36. Ullrich M, Hanus J, Dohnal J, Stepanek F. (2013). Encapsulation stability and temperature-dependent release kinetics from hydrogelimmobilised liposomes. J Colloid Interface Sci 394:380-5.
37. Wen CJ, Zhang LW, Al-Suwayeh SA, et al. (2012). Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomed 7:1599-611.
38. Wilkhu JS, Ouyang D, Kirchmeier MJ, et al. (2013). Investigating the role of cholesterol in the formation of non-ionic surfactant based bilayer vesicles: thermal analysis and molecular dynamics. Int J Pharm 461:331-41.
39. Xiang Y, Liang L, Wang X, et al. (2011). Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 152:402-10.
40. Xie F, Yao N, Qin Y, et al. (2012). Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting. Int J Nanomed 7:163-75.
41. Xu H, Wang KQ, Deng YH, Chen da W. (2010). Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31:4757-63.
42. Xu X, Khan MA, Burgess DJ. (2011). A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 419:52-9.
43. Xu X, Khan MA, Burgess DJ. (2012). A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423:543-53.
44. Yamaguchi T. (1996). Lipid microspheres as drug carriers: a pharmaceutical point of view. Adv Drug Deliv Rev 20:117-30.